Whalesbook
Analyst ka Bharosa Badha, Target ₹1400!
Sabse pehle toh suno, Prabhudas Lilladher waale ne Dr. Reddy's Laboratories ko 'Reduce' se 'Accumulate' pe upgrade kar diya hai, aur stock ka target rakha hai ₹1400. Ye target FY28 ki earnings ke 23x multiple pe based hai, matlab analyst ko company ke future mein kaafi dum lag raha hai. Haan, thoda earnings estimate FY27 aur FY28 ke liye 3-6% kam zaroor kiya hai, par overall view positive hai.
Naye Drugs Laregenge Profit?
Company ne Q4FY26 results report kiye the, jisme kuch one-time items bhi the jaise gRevlimid ka shelf stock adjustment. Par uske alawa, base business ne ₹12 billion ka EBITDA kamaya hai, jisme operating margin 15% ke aas paas tha. Analyst log full confident hain ki Semaglutide ke launch aur overhead costs ko control karke margin ko 21% tak pahunchaya ja sakta hai FY28 tak. Aur toh aur, bAbatacept jaise products bhi FY28 ke second half mein profitability ko boost kar sakte hain. Apni domestic aur Russia markets mein bhi company ka performance solid hai.
Pipeline Power & Valuation Check
Prabhudas Lilladher ko lagta hai ki Dr. Reddy's ka base business margin 15-16% se badh kar FY28 tak 21% ho sakta hai. Ye growth gRevlimid se aaye paison ko peptides, biosimilars, aur GLP-1 drugs jaisi advanced therapies mein reinvest karne se aayegi, jiska fayda FY27 se dikhna start ho sakta hai. Current valuation ki baat karein toh, stock FY28 earnings ke 21x pe trade kar raha hai. Agar competitors se compare karein toh Sun Pharma 22x, Cipla 20x, aur Zydus Lifesciences 28x pe hain. Indian pharma sector mein filhaal moderate growth hai, aur companies specialty generics aur biosimilars pe focus kar rahi hain.
Execution Risks Bhi Hain Yaar!
Abhi sab kuch achha lag raha hai, par investors ko ek bada risk dikh raha hai – Semaglutide ka scaling. Ye drug bahut competitive hai aur market mein entry banana mushkil ho sakta hai. Plus, complex drugs ki R&D costs kaafi zyada hoti hain aur development mein delays ya failure ka bhi chance rehta hai, jo shayad abhi stock price mein fully reflect nahi ho raha hai. Company ko pipeline investment ke liye capital bhi chahiye jo saalon baad return dega, jo short-term cash flow ko thoda impact kar sakta hai. US market mein koi regulatory issue ya pricing pressure bhi margin recovery targets ko affect kar sakta hai.
Aage Kya?
FY27 se Dr. Reddy's ke pipeline investments ka real impact dikhna shuru hoga. Company ka plan long-term growth ka hai. Par FY28 tak 21% operating margins achieve karne ke liye unko multiple complex products successfully launch karne honge aur apni domestic aur international markets mein performance maintain karni hogi. Investors ko management ke execution par nazar rakhni hogi.